Magnus M.
- Country
- Norway
- Department
- 578001: Oncology
Research Overview
- Phase II Open‑Label Multicenter Study of Teclistamab + Pomalidomide in Relapsed/Refractory Multiple Myeloma after 1–3 Prior Lines including Lenalidomide and Anti‑CD38
- Phase 3 Randomized Study of Nemtabrutinib Versus Investigator’s Choice of Ibrutinib or Acalabrutinib in Untreated CLL/SLL
- Phase 3 Open-Label Study of Elranatamab vs. Elotuzumab, Pomalidomide, Dexamethasone, or Carfilzomib in Relapsed/Refractory Multiple Myeloma Post Anti-CD38 Therapy
Data & Insights
Has run more than one trial at 50 of 200 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in the treatment of multiple myeloma, with particular focus on relapsed/refractory disease. Their research encompasses innovative therapeutic approaches for managing multiple myeloma, including monitoring and treatment strategies based on minimal residual disease (MRD) status.
- Multiple Myeloma Management
- MRD-Based Treatment Strategies
- Novel Therapeutic Combinations
The investigator's work includes evaluation of various treatment combinations incorporating modern therapeutic agents for optimal disease control.
Lymphoid Disorders
Research interests extend to follicular lymphoma treatment, particularly focusing on combination immunotherapy approaches. The investigator explores innovative treatment protocols combining targeted therapies with established treatment modalities.
- Follicular Lymphoma Treatment
- Immunotherapy Combinations
- Risk-Adapted Approaches
Their work evaluates the efficacy of novel therapeutic combinations in both high-risk and low-risk disease presentations.
Treatment Innovation
The investigator focuses on developing and evaluating novel therapeutic strategies in hematologic malignancies. This includes research into monoclonal antibody therapies and their combinations with existing treatment modalities.
- Novel Drug Development
- Combination Therapy Optimization
- Treatment Response Assessment
Their research encompasses the evaluation of various therapeutic combinations to enhance treatment outcomes in blood cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.